Drug Price Trends for HUMALOG MIX

Average Pharmacy Cost for HUMALOG MIX

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
HUMALOG MIX 75-25 VIAL	00002-7511-01	8.15102	ML	2026-03-18
HUMALOG MIX 75-25 KWIKPEN	00002-8797-59	10.17432	ML	2026-03-18
HUMALOG MIX 50-50 KWIKPEN	00002-8798-59	10.15166	ML	2026-03-18

Market Analysis and Price Projections for HUMALOG MIX

Last updated: February 13, 2026

Overview

HUMALOG MIX is a combination insulin product by Eli Lilly, used for managing blood glucose levels in diabetes mellitus. Its therapeutic market is influenced by the prevalence of type 1 and type 2 diabetes, competition, regulatory environment, and manufacturing dynamics.

Market Size and Growth

According to the International Diabetes Federation (IDF), global diabetes prevalence was approximately 537 million in 2021, expected to rise to 643 million by 2030.[1] Insulin remains essential for roughly 20-30% of these patients.[2] The market for premixed insulins like HUMALOG MIX accounts for a significant share of this segment.

In 2022, the global insulin market was valued at approximately $24 billion, with premixed insulins representing around 45% of sales.[3] HUMALOG MIX, as a prominent product, constitutes a notable portion within this segment, especially in North America and Europe.

Regulatory and Patent Landscape

HUMALOG MIX was approved by the FDA in 1999. Eli Lilly has maintained patent protections until 2025, with some formulations entering biosimilar competition in certain regions.[4] The expiration of key patents may influence pricing, especially in markets where biosimilars become available.

Competitive Environment

Major competitors include Novo Nordisk’s NovoMix and Sanofi’s Mix 70/30. Biosimilars introduced post-patent expiry threaten pricing stability. For example, in 2021, the first biosimilar insulin glargine (LixiLan) entered select markets at approximately 20-30% lower than brand-name products.

Pricing Dynamics

In the US, wholesale acquisition costs (WAC) for HUMALOG MIX range between $70-$80 per 10 mL vial[5], with patient out-of-pocket costs varying widely due to insurance. In Europe, prices are often lower, typically around €20-30 per vial. Competition and biosimilar entry are expected to exert downward pressure on pricing by 2025.

Price Projections (2023-2028)

• North America: Price stability expected until patent expiry in 2025. Post-2025, a decline of 15-25% anticipated due to biosimilar competition.
• Europe: Slight price reductions of 10-15% owing to market penetration of biosimilars starting in 2024.
• Emerging Markets: Prices remain lower, around $10-$15 per vial, driven by healthcare infrastructure and regulatory frameworks.

Factors Influencing Price Trends

1. Patent expirations in 2025.
2. Approval and uptake of biosimilars.
3. Regulatory policies promoting biosimilar use.
4. Manufacturing costs and supply chain stability.
5. Developments in alternate insulin therapies and delivery devices.

Implications for Stakeholders

• Payers and providers will seek cost reductions post-patent expiry.
• Eli Lilly may adjust pricing strategies to maintain market share.
• Biosimilar entrants will intensify pricing competition, impacting margins.

Summary

HUMALOG MIX remains a significant player in the premixed insulin niche, with solid market position in developed countries. Price stability is forecasted through 2024, with notable declines expected thereafter due to biosimilar competition. The evolving regulatory landscape and patent timelines are critical in shaping future pricing.

---

Key Takeaways

• In 2022, HUMALOG MIX's market share was significant within the premixed insulin segment, especially in North America and Europe.
• The global insulin market is projected to grow from $24 billion in 2022 to over $33 billion by 2030.
• Patent expiration in 2025 will likely lead to a 15-25% price reduction in developed markets.
• Biosimilar competition will intensify from 2024 onwards, pressuring prices downward.
• Pricing strategies must account for regulatory shifts, manufacturing costs, and market penetration of alternative therapies.

---

FAQs

1. When will HUMALOG MIX's patent expire?

   • The key patents are expected to expire in 2025 in the US and Europe.

2. How does biosimilar competition impact pricing?

   • Biosimilars typically enter the market at 20-30% lower prices, leading to competitive price reductions.

3. What are the main markets for HUMALOG MIX?

   • North America, Europe, and select emerging markets.

4. What factors could alter price projections?

   • Changes in regulatory policies, faster biosimilar adoption, manufacturing cost fluctuations, and new insulin formulations.

5. Are innovations like biosimilar insulins affecting market share?

   • Yes, biosimilars are increasingly capturing market share, which may lead to significant pricing adjustments for branded products.

---

References

[1] IDF Diabetes Atlas, 9th Edition, 2019.
[2] American Diabetes Association, Standards of Medical Care in Diabetes, 2022.
[3] MarketsandMarkets, "Insulin Market," 2022.
[4] Eli Lilly, patent information, 2022.
[5] GoodRx, “HUMALOG MIX Price Data,” 2023.